养心氏片联合沙库巴曲缬沙坦钠治疗慢性老年心力衰竭患者的临床效果

Abstract
Figure/Table
References (19)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Yangxinshi Tablets combined with Sacubitril Valsartan Sodium(ARNI)in the treatment of elderly patients with chronic heart failure.Methods A total of 120 elderly patients with CHF admitted to Ji′nan Hospital of Integrated Traditional Chinese and Western Medicine from June 2018 to December 2019 were selected as the research objects and divided into treatment group(60 cases)and control group(60 cases)according to random number table method.The control group was treated with standard treatment,and the treatment group was treated with Yangxinshi Tablets combined with ARNI on the basis of the control group.The total effective rate,left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD)and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment group was higher than that of control group,the difference was statistically significant(P＜0.05).After treatment,LVEF of the two groups were higher than before treatment,while LVEDD were lower than before treatment,and LVEF of the treatment group was higher than that of the control group,LVEDD of the treatment group was lower than that of the control group,the differences were statistically significant(P＜0.05).There were no obvious adverse reactions such as hypotension during treatment in two groups.Conclusion Yangxinshi Tablets combined with ARNI can significantly improve the clinical symptoms of elderly patients with CHF,improve cardiac ultrasound index,reverse ventricular remodeling,and have good safety.

Key words： Chronic heart failure Yangxinshi Tablets Sacubitril Valsartan Sodium Elderly Ultrasonic examination Clinical efficacy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	TANG Ai
	YANG Gui-zhi

Cite this article:

TANG Ai,YANG Gui-zhi. Clinical effect of Yangxinshi Tablets combined with Sacubitril Valsartan Sodium in the treatment of chronic heart failure in elderly patients[J]. 中国当代医药, 2021, 28(15): 73-76.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I15/73

[4]	顾东风，黄广勇，何江，等.中国心力衰竭流行病学调查及其患病率[J].中华心血管病杂志，2003，31（1）：3-6.
[9]	刘红旭，林谦，邢文龙.养心氏片治疗冠心病临床应用中国专家共识[J].中西医结合心脑血管病杂志，2020，18（2）：195-202.
[10]	中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志，2018，46（10）：760-789.
[1]	Vecchis R，Cesaro A，Ariano C.Therapeutic benefits of phosphodi-esterase-5 inhibition in chronic heart failure：a meta-analysis[J].Interv Med Appl Sci，2017，9（3）：123-135.
[2]	Zhang Y，Zhang J，Butler J，et al.Contemporary epidemiology，management，and outcomes of patients hospitalized for heart failure in China：results from the China Heart Failure（China-HF）Registry[J].J Card Fail，2017，23（12）：868-875.
[3]	Petrov VN，Agaeva EV，Popovkina OE，et al.Modifying effect of autotransfusion of mesenchymal stromal cells on the production of reactive oxygen species and cytokines by mononuclear cells in patients with chronic heart failure[J].Bull Exp Biol Med，2017，164（2）：233-240.
[5]	Zile MR，Brutsaert DL.New concepts in diastolic dysfunction and diastolic heart failure：part I:diagnosis.prognosis.measurement of diastolic function[J].Circulation，2002，105（10）：1387-1393.
[6]	Cody RJ，Haas GJ，Binkley PF，et al.Plasma endothelin correlate with the extent of pulmonary hypertension in patients with chronic congestive heart failure[J].Circulation，1992，85（2）：504-509.
[7]	CONSENSUS Trial Study Group.Effects of enalapril on mortality in severe congestive heart failure.Results of the Cooperative North Scandinavian Enalapril Survival Study（CONSENSUS）[J].N Engl J Med，1987，316(23):1429-1435.
[8]	Mc Murray JJ，Packer M，Desai AS，et al.Angiotensi-neprilysin inhibition versus enalapril in heart failure[J].N Engl J Med，2014，371（11）：993-1004.
[11]	司金萍，陈艳伟，杨洁，等.急性失代偿心力衰竭患者早期应用沙库巴曲缬沙坦的有效性和安全性评估[J].中华心血管病杂志，2020，48（6）：477-483.
[12]	季俭，王敏燕，卢英民.曲美他嗪联合瑞舒伐他汀用于冠心病合并心力衰竭的临床疗效[J].武汉大学学报（医学版），2020，18（9）：1-6.
[13]	阎祷.米力农治疗慢性肺心病合并心力衰竭急性加重期的临床疗效观察[J].中国医刊，2012，47（4）：57-58.
[14]	张建军.接轨国际指南、彰显中国特色《中国心力衰竭诊断和治疗指南2018》解读[J].中国临床医生杂志，2019，47（4）：398-402.
[15]	胡盛寿，高润霖，刘力生，等.《中国心血管病报告2018》概要[J].中国循环杂志，2019，34（3）：209-220.
[16]	赵晓琴，沙库巴曲缬沙坦治疗难治性心力衰竭的临床研究[J].现代药物与临床，2020，35（6）：1146-1150.
[17]	谢清清，王辉，曹月娟.养心氏片治疗心血管疾病的研究进展[J].世界中医药，2020，15（5）：801-804.
[18]	高越，陈安妮，赵亚红，等.养心氏片防治慢性缺血性心力衰竭及急性心肌缺血再灌注损伤的实验研究[J].医学实践杂志，2016（5）：403-407.
[19]	孙飞龙，袁炜婷，胡嘉慧，于勤.养心氏片对慢性心力衰竭病人运动耐量和生活质量的影响[J].中西医结合心脑血管病杂志，2019，17（17）：2581-2584.